nach oben

Pediatric Cardiology

Erschienen in:

01.07.2008 | Case Report

Successful Use of Bivalirudin for Superior Vena Cava Recanalization and Stent Placement in a Child with Heparin-Induced Thrombocytopenia

verfasst von: John P. Breinholt, Brady S. Moffett, Karen M. Texter, Frank F. Ing

Erschienen in: Pediatric Cardiology | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening, adverse effect of heparin therapy. Patients with this complication require an alternative approach to anticoagulation. Bivalirudin is a direct thrombin inhibitor with an efficacy comparable to that of heparin, a short half-life, and reduced bleeding complications in adults. We present the case of a 2-year-old boy with HIT Type II who underwent recanalization of an occluded superior vena cava and stent placement, utilizing bivalirudin as anticoagulant.

Almond CS, Harrington J, Thiagarajan R et al (2006) Successful use of bivalirudin for cardiac transplantation in a child with heparin-induced thrombocytopenia. J Heart Lung Transplant 25:1376–1379PubMedCrossRef

Arepally GM, Ortel TL (2006) Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 355:809–817CrossRef

Chew DP, Lincoff AM, Gurm H et al (2005) Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol 95:581–585PubMedCrossRef

Freed MD, Keane JF, Rosenthal A (1974) The use of heparinization to prevent arterial thrombosis after percutaneous cardiac catheterization in children. Circulation 50:565–569PubMed

Girolami B, Prandoni P, Stefani PM et al (2003) The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 101:2955–2959PubMedCrossRef

Huebler M, Koster A, Buz S et al (2006) Cardiopulmonary bypass for complex cardiac surgery using bivalirudin anticoagulation in a patient with heparin antibodies. J Card Surg 21:286–288PubMedCrossRef

Katzen BT, Ardid MI, MacLean AA et al (2005) Bivalirudin as an anticoagulation agent: safety and efficacy in peripheral interventions. J Vasc Interv Radiol 16:1183–1187, quiz 7PubMed

Koster A, Dyke CM, Aldea G et al (2007) Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 83:572–577PubMedCrossRef

Koster A, Spiess B, Chew DP et al (2004) Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Am J Cardiol 93:356–359PubMedCrossRef

10.

Koster A, Spiess B, Jurmann M et al (2006) Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the “EVOLUTION OFF” trial. Anesth Analg 103:540–544PubMedCrossRef

11.

Koster A, Weng Y, Bottcher W, Gromann T, Kuppe H, Hetzer R (2007) Successful use of bivalirudin as anticoagulant for ECMO in a patient with acute HIT. Ann Thorac Surg 83:1865–1967PubMedCrossRef

12.

Lincoff AM, Bittl JA, Harrington RA et al (2003) Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289:853–863PubMedCrossRef

13.

Lincoff AM, Kleiman NS, Kereiakes DJ et al (2004) Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 292:696–703PubMedCrossRef

14.

Murphy GS, Marymont JH (2007) Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery. J Cardiothorac Vasc Anesth 21:113–126PubMedCrossRef

15.

Pappalardo F, Franco A, Crescenzi G, Poli A, Zangrillo A, Koster A (2007) Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin allergy. Perfusion 22:67–69PubMedCrossRef

16.

Ranze O, Ranze P, Magnani HN, Greinacher A (1999) Heparin-induced thrombocytopenia in paediatric patients–a review of the literature and a new case treated with danaparoid sodium. Eur J Pediatr 158(Suppl 3):S130–S133PubMedCrossRef

17.

Risch L, Huber AR, Schmugge M (2006) Diagnosis and treatment of heparin-induced thrombocytopenia in neonates and children. Thromb Res 118:123–135PubMedCrossRef

18.

Seybert AL, Coons JC, Zerumsky K (2006) Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin? Pharmacotherapy 26:229–241PubMedCrossRef

19.

Shammas NW, Allie D, Hall P et al (2005) Predictors of in-hospital and 30-day complications of peripheral vascular interventions using bivalirudin as the primary anticoagulant: results from the APPROVE Registry. J Invasive Cardiol 17:356–359PubMed

20.

Shammas NW, Lemke JH, Dippel EJ et al (2003) Bivalirudin in peripheral vascular interventions: a single center experience. J Invasive Cardiol 15:401–404PubMed

21.

Stone GW, White HD, Ohman EM et al (2007) Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 369:907–919PubMedCrossRef

22.

Weitz JI, Bates SM (2002) Acute coronary syndromes: a focus on thrombin. J Invasive Cardiol 14(Suppl B):2B–7BPubMed

23.

Young G, Tarantino MD, Wohrley J, Weber LC, Belvedere M, Nugent DJ (2007) Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis. J Thromb Haemost 5:1654–1659PubMedCrossRef

Titel: Successful Use of Bivalirudin for Superior Vena Cava Recanalization and Stent Placement in a Child with Heparin-Induced Thrombocytopenia
verfasst von: John P. Breinholt
Brady S. Moffett
Karen M. Texter
Frank F. Ing
Publikationsdatum: 01.07.2008
Verlag: Springer-Verlag
Erschienen in: Pediatric Cardiology / Ausgabe 4/2008
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI: https://doi.org/10.1007/s00246-008-9231-2

Neu im Fachgebiet Kardiologie

19.04.2024 | Vorhofflimmern | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Successful Use of Bivalirudin for Superior Vena Cava Recanalization and Stent Placement in a Child with Heparin-Induced Thrombocytopenia

Abstract

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2008

Familial Hypertrophic Cardiomyopathy Associated with Cardiac β-Myosin Heavy Chain and Troponin I Mutations

Medication Dosing and Renal Insufficiency in a Pediatric Cardiac Intensive Care Unit: Impact of Pharmacist Consultation

Correlation Between Right Ventricular Tei Index by Tissue Doppler Imaging and Pulsed Doppler Imaging in Fetuses

Transcatheter Management of Subtotal Cor Triatriatum Sinister: A Rare Anomaly

Mixed Supra- and Infradiaphragmatic Totally Anomalous Pulmonary Venous Connection in an Adolescent

PHACES Association: A Vasculocutaneous Syndrome

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie